- Home
- NMAI vs CVRX Comparison
NMAI vs CVRX Comparison
Compare NMAI & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMAI
- CVRX
- Stock Information
- Founded
- NMAI 2021
- CVRX 2000
- Country
- NMAI United States
- CVRX United States
- Employees
- NMAI N/A
- CVRX N/A
- Industry
- NMAI Investment Managers
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NMAI Finance
- CVRX Health Care
- Exchange
- NMAI Nasdaq
- CVRX Nasdaq
- Market Cap
- NMAI 378.7M
- CVRX 419.8M
- IPO Year
- NMAI N/A
- CVRX 2021
- Fundamental
- Price
- NMAI $11.53
- CVRX $6.25
- Analyst Decision
- NMAI
- CVRX Strong Buy
- Analyst Count
- NMAI 0
- CVRX 7
- Target Price
- NMAI N/A
- CVRX $16.83
- AVG Volume (30 Days)
- NMAI 74.8K
- CVRX 516.2K
- Earning Date
- NMAI 01-01-0001
- CVRX 05-08-2025
- Dividend Yield
- NMAI 13.14%
- CVRX N/A
- EPS Growth
- NMAI N/A
- CVRX N/A
- EPS
- NMAI 0.64
- CVRX N/A
- Revenue
- NMAI N/A
- CVRX $51,292,000.00
- Revenue This Year
- NMAI N/A
- CVRX $22.17
- Revenue Next Year
- NMAI N/A
- CVRX $24.02
- P/E Ratio
- NMAI $19.03
- CVRX N/A
- Revenue Growth
- NMAI N/A
- CVRX 30.53
- 52 Week Low
- NMAI $10.60
- CVRX $5.87
- 52 Week High
- NMAI $12.55
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- NMAI 45.37
- CVRX 25.78
- Support Level
- NMAI $10.75
- CVRX $5.91
- Resistance Level
- NMAI $11.55
- CVRX $6.71
- Average True Range (ATR)
- NMAI 0.32
- CVRX 0.84
- MACD
- NMAI 0.02
- CVRX -0.43
- Stochastic Oscillator
- NMAI 67.66
- CVRX 5.28
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment strategy uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.